Dysport® Shows Positive Phase III Results for Migraine Prevention

Ipsen has reported successful Phase III clinical trial results for its drug Dysport®, indicating its effectiveness in reducing monthly migraine days. The trials showed significant benefits for adults suffering from both episodic and chronic migraines. This marks a notable achievement as it is the first botulinum toxin to prove efficacy in episodic migraine prevention during a Phase III study.